Bioceltech allogeneic CAR-T therapy

Bioceltech Therapeutics Beijing is developing an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, often referred to as Universal CAR-T (UCAR-T), for the treatment of hematologic malignancies including leukemia and lymphoma. Unlike traditional autologous CAR-T therapies that require a bespoke manufacturing process using a patient's own T cells, this allogeneic approach utilizes T cells from healthy donors. These cells are engineered to express a CAR targeting specific tumor antigens, most commonly CD19 for B-cell malignancies. To ensure safety and efficacy in an off-the-shelf format, Bioceltech employs proprietary technology designed to prevent graft-versus-host disease (GvHD) and minimize immune rejection by the recipient, reportedly using a non-gene-edited approach. This modality aims to provide a standardized, readily available, and more cost-effective treatment option, addressing the significant logistical and manufacturing challenges associated with personalized cell therapies.

Other names

异体CAR-TUniversal CAR-TBioceltech universal CAR-T therapyallogeneic CAR-T therapy (Bioceltech Therapeutics Beijing)